Mizuho Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

By Jason Carr

Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report) today and set a price target of $183.00. The company’s shares closed last Friday at $139.34.

According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.8% and a 32.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Revance Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $195.62, representing a 52.6% upside. In a report issued on May 6, RBC Capital also maintained a Buy rating on the stock with a $180.00 price target.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $114 million and GAAP net loss of $17.49 million. In comparison, last year the company earned revenue of $87.01 million and had a GAAP net loss of $76.64 million.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in March 2020, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 5,000 shares for a total of $584,450.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.